A novel CBD pharmaceutical drug — if approved by the FDA — will have a path to pharmacies in Colorado.
Gov. John Hickenlooper this week signed , which allows for doctors to prescribe and pharmacies to dispense FDA-approved medicines that contain cannabidiol, a nonpsychoactive cannabis plant compound.
The was Epidiolex, a CBD-centric drug for rare seizure disorders. , via its U.S. subsidiary Greenwich Biosciences, developed Epidiolex utilizing plant-derived cannabis compounds but hit roadblocks on the state level because of marijuana’s Schedule I designation.
In Colorado, the bill signed Monday sought to address a state statute that prevented pharmacies from dispensing cannabis products.
The U.S. Food and Drug Administration is expected to issue a decision on Epidiolex’s new drug application by the end of this month. In April, an gave a unanimous recommendation for approval.
Members of the hemp and marijuana industries have expressed concerns that Epdiolex’s approval could ultimately . House Bill 1187 included language to provide guardrails for the state’s existing extracts businesses.
